In part 6 of this Exclusive Interview, Dr. Ronald Swerdloff talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the key takeaways from his presentation about male hypogonadism.
Ronald Swerdloff, MD is a professor of medicine at David Geffen School of Medicine at UCLA, the chief of division of endocrinology and metabolism at the Harbor UCLA Medical Center, and the senior investigator at the LA Biomedical Research Institute.
Transcript of this video segment:
Steve: I just read an article and they were talking about what makes a good presenter. The findings are that the good presenter is someone that presents their material and the audience takes it home and uses that information, and that medical medical community uses it with their patients. There there are people who have 150 beautiful slides, but you walk out of the door, and you can’t remember a darn thing. It’s a waste of everybody’s time. If you had your druthers what points would you like your audience to take away, so that you don’t waste your time or the audience, and that they are going to put it in their practice?
Dr. Swerdloff: So the first thing that I would want people to recognize is that people with diabetes have a high chance of having low testosterone. And that low testosterone is for the most part driven by failure to be able to produce the normal amount of signals from the pituitary gland – it’s called secondary hypogonadism. That if those symptoms are such that they are clinically important to the patient then they should be treated with testosterone if the value of testosterone is repeatedly low and if the patient has the symptoms that you talk about. Then, I would like people to know that we don’t know for certain whether testosterone treatment will improve glycemic control but there is some evidence to suggest that and we need more data in order to resolve the issue.
Steve: Right now, are there any studies going on to resolve that issue?
Dr. Swerdloff: Yes, there are studies going on to resolve the issue, they are what is called long-term safety studies. They don’t specifically at this time deal with whether or not that improves the blood sugar in diabetics. That study has been done, but it has not been done in the placebo-controlled, evidence-based type of fashion that would convince everybody. That study needs to be done, but it’s a little bit difficult to do because these are people that are on a number of medications and you have to be able to sort out the medication effects in addition to the treatment with testosterone. These are really important issues that need to be resolved and they will be resolved as we go forward.